occupational therapy to help you cope with the day-to-day problems.physiotherapy to help with movement problems.speech and language therapy to help with speech and swallowing problems.In most cases, there's no cure for ataxia and supportive treatment to control the symptoms is necessary. Hereditary ataxia is caused by a faulty gene passed on by family members, who may or may not be affected. This damage can be part of an underlying condition such as MS, or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. What causes ataxia?Ītaxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. Read more about the main types of ataxia. idiopathic late-onset cerebellar ataxia (ILOCA) – where the brain is progressively damaged over time for reasons that are unclear.hereditary ataxia – where symptoms develop slowly over many years and are caused by faulty genes that a person inherits from their parents the most common type is Friedreich's ataxia.acquired ataxia – where symptoms develop as the result of trauma, a stroke, multiple sclerosis (MS), a brain tumour, nutritional deficiencies, or other problems that damage the brain or nervous system.There are many different types of ataxia, which can be divided into three broad categories:
The exact symptoms and their severity vary depending on the type of ataxia a person has. tasks that require a high degree of control, such as writing and eating.Terms of Use and Privacy Policy ( ).Ataxia is a term for a group of disorders that affect co-ordination, balance and speech.Īny part of the body can be affected, but people with ataxia often have difficulties with: The use of YourMS™ is solely at the discretion of the relevant HCP(s) involved in the care and treatment of the patient, and the Novartis Group of companies hereby disclaims all warranties, whether express, implied or statutory, including but not limited to the implied warranties of merchantability and fitness for a particular purpose are hereby disclaimed and excluded to the fullest extent of the law. Any medical advice, diagnosis or treatment must be made in conjunction with all other available clinical information regarding the patient by an appropriate HCP. It does not provide medical advice, diagnosis, prediction, prognosis or treatment advice. YourMS™ is a patient questionnaire for use by HCPs with their patients in clinical practice, aimed at facilitating and supporting HCP–patient interactions.
This website does not collect any personal data, however, please refer to the Privacy Policy below to learn how Novartis manages personal data collected via its websites. The Novartis Group of companies (in the UK, Novartis Pharmaceuticals UK Limited) does not collect any patient data from YourMS™ access to the information arising from this questionnaire is solely between the relevant HCP and the patient completing it. YourMS™ was developed and funded by Novartis Pharma AG. Presentation at Consortium of Multiple Sclerosis Centers Annual Meeting, October 28 2021, Orlando, Florida.
#Ms symptoms checklist nhs professional
HCP, healthcare professional MS, multiple sclerosis SPMS, secondary progressive multiple sclerosis.
TAFINLAR (dabrafenib) + MEKINIST (trametinib) in Melanoma.TAFINLAR + MEKINIST in non-small cell lung cancer (NSCLC).
0 kommentar(er)
